Cancer combo trial pulled before it even started
NCT ID NCT06084689
First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This study was designed to test a combination of two drugs, Ezabenlimab and BI907828, in people with advanced solid tumors like sarcoma, lung cancer, and breast cancer. The goal was to see if the treatment could control the disease for at least 24 weeks. However, the trial was withdrawn before enrolling any participants, so no data or conclusions are available.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Ezabenlimab and BI907828
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADULT SOFT TISSUE SARCOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CHRU Poitiers
Poitiers, France
-
Centre Eugène Marquis
Rennes, France
-
Centre Georges François Leclerc
Dijon, France
-
Centre Léon Bérard
Lyon, France
-
Centre Oscar Lambret
Lille, 59000, France
-
Institut Bergonié
Bordeaux, 33076, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a plasma beam stop colon polyps from coming back?
- A stitch in time: could a device make abdominal closure safer?
- Can we predict chemo brain before it happens?
- Can a new immunotherapy combo outsmart advanced lung cancer?
- Your gut bacteria might reveal hidden cancer risk
- Can a smart digital program restore sleep for cancer survivors?